Conditions
Essential Thrombocythemia
Clinical Trials
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea.
The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
CLINICALTRIALS.GOV IDENTIFIER
NCT06079879
EU CT Number
2023-504865-21
When you talk with your doctor or clinical trial team member, please have the trial identifier number available.
Only a qualified healthcare professional can determine if you are eligible to take part in a clinical trial. However, this information may be useful in starting a conversation with your doctor.
Conditions
Essential Thrombocythemia
Age Range
18+
Sex
All
All patients who enroll in the trial will receive the investigational medication or a best available treatment while on the study.
50% will receive bomedemstat
50% will receive the best available treatment (anagrelide, busulfan, interferon, or ruxolitinib). The trial doctor will tell you which drug you will get if you are put in Group 2.
*A computer will decide which group you are put in. You have an equal chance of being placed in either group.
In Phase 3 trials, researchers try to find out if a treatment works in a large number of people, usually about 1,000 to 5,000 participants who have the health condition the treatment is intended to treat. In vaccine trials, the participants may be healthy or have diseases or conditions. Phase 3 trials may happen in a doctor’s office, a clinic, or a hospital.
Locations shown may have changed in some cases. Please call the number listed in the location results to confirm the nearest trial site. Talk with a trial site member for more information.
If you think this clinical trial might be a good fit and you are interested in taking part, take the next step to see if you are eligible.
If you are considering joining a clinical trial, first learn as much as you can about:
Talk to your doctor about the clinical trial before you decide to join.
Read our “What to Consider” page for more questions to ask and think about